AUS
NZ
UK
CA
USA
IND
Headlines
- Cardiol Therapeutics has a cash runway of approximately 15 months.
- The company's cash burn remains steady, raising questions about future growth.
- Potential dilution if more cash is raised through equity.
Attracting interest in unprofitable companies is a common phenomenon among investors. Companies in sectors like biotechnology and mining exploration often operate at a loss for years before discovering groundbreaking treatments or significant mineral deposits. However, the high-profile successes shouldn't overshadow the numerous unprofitable firms that exhaust their funds without achieving profitability.
Cardiol Therapeutics Inc. (TSE:CRDL) entered the spotlight with its cash burn situation posing questions for its shareholders. Defined as the annual negative free cash flow, cash burn represents the money a company uses yearly to fuel its growth. It's essential to understand the firm's cash reserves in relation to its cash burn to gain insights into its financial health.
Evaluating Cardiol Therapeutics' Financial Outlook
As of December 2024, Cardiol Therapeutics boasted CA$31 million in cash with no debt. Considering the company had a cash burn of CA$25 million over the preceding twelve months, it suggests a cash runway nearing 15 months from that date. While this timeframe might appear comfortable, prudent investors would closely monitor the situation, considering future scenarios if the cash reserves deplete.
Monitoring Cash Burn Over Time
Cardiol Therapeutics, currently in its early business stages without revenue influx, maintained a stable cash burn within the last year. This situation hints that the management is controlling expenditures while the company advances its strategies. Nonetheless, a pivotal factor is the company's ability to grow its business moving forward.
Assessing Future Capital Raising Prospects
With an eye on its future resource needs, shareholders should examine how effortlessly Cardiol Therapeutics can gather additional funds. Typically, companies procure capital through debt or equity, often opting to issue new shares to support future expansion. Given a market capitalization of CA$112 million, the company's cash burn accounts for about 22% of its market value, indicating that any necessary equity raising might lead to significant shareholder dilution.
Summary of Concerns and Considerations
Although the cash burn relative to market capitalization raises some caution, Cardiol Therapeutics' cash runway seems satisfactory for now. Nonetheless, stakeholders should diligently contemplate the potential challenges involved in obtaining further financing. Future risks identified include five warning signs for Cardiol Therapeutics, two of which stand out in significance.
For a broader range of investment opportunities, consider exploring lists of companies with high return on equity or those featuring substantial insider ownership.
